Lidia Usnarska‐Zubkiewicz

Central nervous system involvement by multiple myeloma: A multi‐institutional retrospective study of 172 patients in daily clinical practice

Artur Jurczyszyn, Norbert Grząśko, Alessandro Gozzetti et al. · American Journal of Hematology · 2016 · 141 citations · Full text

Medicine, Hematology, Oncology +14

Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial

Dominik Dytfeld, Tomasz Wróbel, Krzysztof Jamroziak et al. · The Lancet Oncology · 2023 · 74 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

2-Chlorodeoxyadenosine (2-CdA) in 2-Hour Versus 24-Hour Intravenous Infusion in the Treatment of Patients with Hairy Cell Leukemia

Tadeusz Robak, Maria Błasińska-Morawiec, E Krykowski et al. · Leukemia & lymphoma/Leukemia and lymphoma · 1996 · 68 citations

Medicine, Hematology, Pharmacology +8

Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy

Dominik Dytfeld, Magdalena Łuczak, Tomasz Wróbel et al. · Oncotarget · 2016 · 68 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Meletios Α. Dimopoulos, Paul G. Richardson, Nizar J. Bahlis et al. · The Lancet Haematology · 2022 · 47 citations

Medicine, Oncology, Pharmacotherapy +12